Different effects of Bifeprunox, Aripiprazole, and Haloperidol on body weight gain, food and water intake, and locomotor activity in rats

Pharmacology Biochemistry and Behavior

Volumn 124, Issue , 2014, Pages 167-173

  De Santis, Michael ^a   Pan, Bo ^a   Lian, Jiamei ^a   Huang, Xu Feng ^a   Deng, Chao ^a  

^a UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

Antipsychotic; Aripiprazole; Bifeprunox; Body weight; Haloperidol; Locomotor activity

Indexed keywords

ARIPIPRAZOLE; BIFEPRUNOX; HALOPERIDOL; BENZOXAZOLE DERIVATIVE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FAT MASS; FLUID INTAKE; FOOD INTAKE; LIPID STORAGE; LOCOMOTION; LONG TERM CARE; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; TREATMENT DURATION; WEIGHT GAIN; WEIGHT REDUCTION; WHITE ADIPOSE TISSUE; ANIMAL; DRINKING BEHAVIOR; DRUG EFFECTS; FEEDING BEHAVIOR; MOTOR ACTIVITY; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZOXAZOLES; DRINKING BEHAVIOR; FEEDING BEHAVIOR; HALOPERIDOL; MALE; MOTOR ACTIVITY; PIPERAZINES; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY; WEIGHT GAIN;

EID: 84903179140     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2014.06.004     Document Type: Article

References (73)

1. O. Agid, S. Kapur, and G. Remington Emerging drugs for schizophrenia Expert Opin Emerg Drugs 13 3 2008 479 495
2. A.A. Arjona, S.X. Zhang, B. Adamson, and R.J. Wurtman An animal model of antipsychotic-induced weight gain Behav Brain Res 152 1 2004 121 127 (Pubitemid 38597070)
3. J. Arnt, M.B. Hesselink, M. Didriksen, J.A. van der Heijden, R.W. Feenstra, and C.G. Kruse DU127090: a novel partial dopamine agonist with antipsychotic activity a putative potent full spectrum antipsychotic with low EPS potential Schizophr Res 60 1, Supplement 2003 104
4. M.B. Assié, H. Dominguez, N. Consul-Denjean, and A. Newman-Tancredi In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles Naunyn Schmiedebergs Arch Pharmacol 373 6 2006 441 450 (Pubitemid 44401414)
5. L.M. Barbato, S.G. Potkin, J. Heisterberg, P.P. Yeung, and N.A. Shapira A randomized, double-blind, placebo-controlled study of Bifeprunox, a partial dopamine D2 receptor agonist, in patients with acute exacerbations of schizophrenia Neuropsychopharmacology 31 S1 2006 S251 [abstract 134]
6. L. Bardin, A. Auclair, M.S. Kleven, E.P.M. Prinssen, W. Koek, and A. Newman-Tancredi et al. Pharmacological profiles in rats of novel antipsychotics with combined dopamine d-2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics Behav Pharmacol 18 2 2007 103 118 [[Article]. Mar] (Pubitemid 46398960)
7. H.R. Berthoud Multiple neural systems controlling food intake and body weight Neurosci Biobehav Rev 26 4 2002 393 428
8. J. Bhattacharjee, and H.G. El-Sayeh Aripiprazole versus typical antipsychotic drugs for schizophrenia Cochrane Database Syst Rev 2008 3
9. D. Bishara, and D. Taylor Upcoming agents for the treatment of schizophrenia Drugs 68 16 2008 2269 2292
10. A. Bortolozzi, L. Díaz-Mataix, M. Toth, P. Celada, and F. Artigas In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain Psychopharmacology (Berl) 191 3 2007 745 758 (Pubitemid 46355906)
11. K.D. Burris, T.F. Molski, C. Xu, E. Ryan, K. Tottori, and T. Kikuchi et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors J Pharmacol Exp Ther 302 1 2002 381 389 [2002 July 1] (Pubitemid 34680462)
12. D.E. Casey, E.E. Sands, J. Heisterberg, and H.M. Yang Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study Psychopharmacology (Berl Ger) 200 3 2008 317 331
13. R.R. Conley, and D.L. Kelly Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effects Isr J Psychiatry Relat Sci 42 1 2005 51 60 (Pubitemid 41159764)
14. C.U. Correll From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics Eur Psychiatry 25 Supplement 2 2010 S12 S21
15. I. Creese, D.R. Burt, and S.H. Snyder Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs J Neuropsychiatr 8 2 1996
16. L. Dahan, H. Husum, O. Mnie-Filali, J. Arnt, P. Hertel, and N. Haddjeri Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour J Psychopharmacol 23 2 2009 177 189 [2009 March 1]
17. A. DeLeon, N.C. Patel, and M. Lynn Crismon Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability Clin Ther 26 5 2004 649 666 10.1016/S0149-2918(04)90066-5 (Pubitemid 38736956)
18. C. Deng Effects of antipsychotic medications on appetite, weight, and insulin resistance Endocrinol Metab Clin North Am 42 3 2013 545 563
19. C. Deng, K.L. Weston-Green, M. Han, and X.F. Huang Olanzapine treatment decreases the density of muscarinic M2 receptors in the dorsal vagal complex of rats Prog Neuropsychopharmacol Biol Psychiatry 31 4 2007 915 920 (Pubitemid 46660303)
20. C. Deng, J. Chen, C. Hu, and X.F. Huang What is the mechanism for aripiprazole's effect on reducing olanzapine-associated obesity? J Clin Psychopharmacol 30 4 2010 480
21. C. Deng, J. Lian, N. Pai, and X.F. Huang Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model J Psychopharmacol 26 6 2012 [06/2012]
22. C. Deng, J. Lian, N. Pai, and X.F. Huang Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model J Psychopharmacol 26 9 2012 1271 1279 [2012 September 1]
23. A. Di Clemente, C. Franchi, A. Orru, J. Arnt, and L. Cervo Bifeprunox: a partial agonist at dopamine D2 and serotonin1A receptors, influences nicotine-seeking behaviour in response to drug-associated stimuli in rats Addict Biol 17 2 2012 274 286
24. T.M. du Bois, X.F. Huang, and C. Deng Perinatal administration of PCP alters adult behaviour in female Sprague-Dawley rats Behav Brain Res 188 2 2008 416 419
25. R. Emsley Drugs in development for the treatment of schizophrenia Expert Opin Investig Drugs 18 8 2009 1103 1118
26. A. Etievant, C. Betry, J. Arnt, and N. Haddjeri Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation Neurosci Lett 460 1 2009 82 86 10.1016/j.neulet.2009.05.035
27. R.W. Feenstra, J. de Moes, J.J. Hofma, H. Kling, W. Kuipers, and S.K. Long et al. New 1-aryl-4-(biarylmethylene)piperazines as potential atypical antipsychotics sharing dopamine D2-receptor and serotonin 5-HT1A-receptor affinities Bioorg Med Chem Lett 11 17 2001 2345 2349 (Pubitemid 32781696)
28. R.R. Gainetdinov Mesolimbic dopamine in obesity and diabetes Am J Physiol Regul Integr Comp Physiol 293 2007 601 602
29. B.M. Geiger, M. Haburcak, N.M. Avena, M.C. Moyer, B.G. Hoebel, and E.N. Pothos Deficits of mesolimbic dopamine neurotransmission in rat dietary obesity Neuroscience 159 4 2009 1193 1199
30. T. Hamamura, and T. Harada Unique pharmacological profile of aripiprazole as the phasic component buster Psychopharmacology (Berl Ger) 191 3 2007 741 743 (Pubitemid 46355901)
31. M. Han, C. Deng, T.H.J. Burne, K.A. Newell, and X.-F. Huang Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression Psychoneuroendocrinology 33 5 2008 569 580 10.1016/j.psyneuen.2008. 01.018
32. M. Han, X.F. Huang, and C. Deng Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects Int J Neuropsychopharmacol 12 2009 941 952
33. M. Han, X.F. Huang, T.M. du Bois, and C. Deng The effects of antipsychotic drugs administration on 5-HT1A receptor expression in the limbic system of the rat brain Neuroscience 164 4 2009 1754 1763
34. M. He, C. Deng, and X.F. Huang The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain CNS Drugs 27 6 2013 423 434 [2013/06/01]
35. D.C. Henderson, L. Kunkel, D.D. Nguyen, C.P. Borba, T.B. Daley, and P.M. Louie et al. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia Acta Psychiatr Scand 113 2006 142 147 (Pubitemid 43340908)
36. D.C. Henderson, X. Fan, P.M. Copeland, B. Sharma, C.P. Borba, and R. Boxill et al. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients J Clin Psychopharmacol 29 2 2009 165 169
37. A.H.J. Herremans, P. Hertel, H. Husum, K. Marquis, J. Van der Heyden, and A.C. McCreary et al. Bifeprunox: a novel atypical antipsychotic with in vivo 5-HT1A receptor agonistic activity Eur Neuropsychopharmacol 15 Supplement 3(0) 2005 S488
38. X.F. Huang, M. Han, and L.H. Storlien Differential expression of 5-HT2A and 5-HT2C receptor mRNAs in mice prone, or resistant, to chronic high-fat diet-induced obesity Mol Brain Res 127 1-2 2004 39 47 (Pubitemid 39089094)
39. X.F. Huang, M. Han, K. Zavitsanou, and C. Deng Olanzapine differently affects 5-HT2a and 2c receptor mRNA expression in the rat brain Behav Brain Res 171 2006 355 362 (Pubitemid 43946500)
40. S. Kapur, S.C. VanderSpek, B.A. Brownlee, and J.N. Nobrega Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy J Pharmacol Exp Ther 305 2 2003 625 631 [2003 May 1] (Pubitemid 36459179)
41. J.A. Lieberman Dopamine partial agonists: a new class of antipsychotic CNS Drugs 18 4 2004 251 + [Article]
42. J.A. Lieberman, T.S. Stroup, and J.P. McEvoy Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med 353 12 2005 1209 1223 (Pubitemid 41345943)
43. R.B. Mailman, and V. Murthy Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des 16 5 2010 488 501
44. 1A receptor occupancy in patients with schizophrenia: a triple tracer PET study Am J Psychiatry 164 9 2007 1411 1417 (Pubitemid 47461142)
45. H.Y. Meltzer, E. Perry, and K. Jayathilake Clozapine-induced weight gain predicts improvement in psychopathology Schizophr Res 59 1 2003 19 27 (Pubitemid 35291087)
46. D.V. Naiker, S.V. Catts, V.S. Catts, K.S. Bedi, and L.J. Bryan-Lluka Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat Eur J Pharmacol 540 1-3 2006 87 90 (Pubitemid 43866708)
47. H.A. Nasrallah Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles Mol Psychiatry 13 1 2008 27 35 (Pubitemid 350275185)
48. S. Natesan, G.E. Reckless, J.N. Nobrega, P.J. Fletcher, and S. Kapur Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models Neuropsychopharmacology 31 9 2006 1854 1863
49. S. Natesan, G.E. Reckless, K.B.L. Barlow, J.N. Nobrega, and S. Kapur Partial agonists in schizophrenia - why some work and others do not: insights from preclinical animal models Int J Neuropsychopharmacol 14 09 2011 1165 1178
50. A. Newman-Tancredi, M.B. Assie, N. Leduc, A.M. Ormiere, N. Danty, and C. Cosi Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia Int J Neuropsychopharmacol 8 03 2005 341 356 (Pubitemid 41002489)
51. A. Newman-Tancredi, D. Cussac, and R. Depoortere Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation anti psychotics Curr Opin Investig Drugs 8 7 2007 539 554 (Pubitemid 47016322)
52. R.J. Olds, and J.R. Olds A colour atlas of the rat: dissection guide 1979 Wolfe Medical London
53. F. Panariello, V. De Luca, and A. de Bartolomeis Weight gain, schizophrenia and antipsychotics: new findings from animal model and pharmacogenomic studies Schizophr Res Treat 2011 16 10.1155/2011/459284
54. J.K. Patel, P.F. Buckley, S. Woolson, R.M. Hamer, J.P. McEvoy, and D.O. Perkins et al. Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study Schizophr Res 111 1-3 2009 9 16
55. S. Reagan-Shaw, M. Nihal, and N. Ahmad Dose translation from animal to human studies revisited FASEB J 22 3 2008 659 661 [2008 March 1] (Pubitemid 351348146)
56. G.P. Reynolds, and S.L. Kirk Metabolic side effects of antipsychotic drug treatment - pharmacological mechanisms Pharmacol Ther 125 1 2010 169 179
57. B. Scatton, and D.J. Sanger Pharmacological and molecular targets in the search for novel antipsychotics Behav Pharmacol 11 2000 243 256 (Pubitemid 30449756)
58. P. Seeman, T. Lee, M. Chau-Wong, and K. Wong Antipsychotic drug doses and neuroleptic/dopamine receptors Nature 261 5562 1976 717 719 10.1038/261717a0
59. D.A. Shapiro, S. Renock, E. Arrington, L.A. Chiodo, L. Li-Xin, and D.R. Sibley et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology Neuropsychopharmacology 28 8 2003 1400 1411 (Pubitemid 41070874)
60. E. Stip, and V. Tourjman Aripiprazole in schizophrenia and schizoaffective disorder: a review Clin Ther 32 Supplement 1 2010 S3 S20 10.1016/j.clinthera.2010.01.021
61. D. Tarsy, and R.J. Baldessarini Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord 21 5 2006 589 598 (Pubitemid 43792739)
62. H. Ujike, A. Nomura, Y. Morita, A. Morio, Y. Okahisa, and T. Kotaka et al. Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study J Clin Psychiatry 69 2008 1416 1422
63. J.D. Urban, G.A. Vargas, M. von Zastrow, and R.B. Mailman Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways Neuropsychopharmacology 32 1 2006 67 77
64. N.D. Volkow, and R.A. Wise How can drug addiction help us understand obesity? Nat Neurosci 8 5 2005 555 560 (Pubitemid 40594193)
65. N.D. Volkow, G.J. Wang, J.S. Fowler, J. Logan, M. Jayne, and D. Franceschi et al. "Nonhedonic" food motivation in humans involves dopamine in the dorsal striatum and methylphenidate amplifies this effect Synapse 44 3 2002 175 180 (Pubitemid 34303915)
66. N.D. Volkow, G.J. Wang, and R.D. Baler Reward, dopamine and the control of food intake: implications for obesity Trends Cogn Sci 15 1 2011 37 46
67. M.L.G. Wadenberg Bifeprunox: a novel antipsychotic agent with partial agonist properties at dopamine D2 and serotonin 5-HT1A receptors Future Neurol 2 2 2007 153 165
68. G.J. Wang, N.D. Volkow, and J.S. Fowler The role of dopamine in motivation for food in humans: implications for obesity Expert Opin Ther Targets 6 5 2002 601 609 (Pubitemid 35175108)
69. K. Weston-Green, X.F. Huang, M. Han, and C. Deng The effects of antipsychotics on the density of cannabinoid receptors in the dorsal vagal complex of rats: implications for olanzapine-induced weight gain Int J Neuropsychopharmacol 11 06 2008 827 835
70. K. Weston-Green, X.F. Huang, and C. Deng Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats Behav Brain Res 217 2 2011 337 346 10.1016/j.bbr.2010.10.039
71. M. Wood, and C. Reavill Aripiprazole acts as a selective dopamine D2 receptor partial agonist Expert Opin Investig Drugs 16 6 2007 771 775 [2007/06/01] (Pubitemid 46882352)
72. F. Yokoi, G. Gründer, K. Biziere, S. Massoud, A.S. Dogan, and R.F. Dannals et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]Raclopride Neuropsychopharmacology 27 2 2002 248 259 (Pubitemid 34692591)
73. R.B. Zipursky, H. Gu, A.I. Green, D.O. Perkins, M.F. Tohen, and J.P. McEvoy et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol Br J Pharmacol 187 2005 537 543